Applying molecular measurable residual disease testing in acute myeloid leukaemia
- Author(s)
- Krigstein, M; Iland, HJ; Wei, AH;
- Details
- Publication Year 2023-02,Volume 55,Issue #1,Page 1-7
- Journal Title
- Pathology
- Publication Type
- Review
- Abstract
- Molecular testing in acute myeloid leukaemia (AML) has continued to dramatically advance in recent years, facilitating the ability to detect residual disease at exponentially lower levels. With the advent of the recently updated ELN consensus recommendations, there is increasing complexity to ordering and interpreting measurable residual disease (MRD) assays in AML. We outline the technology itself in conjunction with the relevant testing timepoints, clinically significant thresholds and potential prognostic and therapeutic significance of MRD testing for the major molecular targets in AML. This practical overview should assist haematologists in incorporating molecular MRD assays routinely into their personalised AML clinical management.
- Publisher
- Elsevier
- Keywords
- Humans; *Leukemia, Myeloid, Acute/diagnosis/genetics; Prognosis; Neoplasm, Residual/diagnosis; Molecular Diagnostic Techniques; Flt3; Measurable residual disease; Npm1; acute myeloid leukaemia; clonal haematopoiesis
- Department(s)
- Clinical Haematology
- PubMed ID
- 36503638
- Publisher's Version
- https://doi.org/10.1016/j.pathol.2022.11.003
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-05-30 07:27:56
Last Modified: 2023-05-30 07:28:52